WARNER-LAMBERT's FIRST PROJECT IN CHINA IS HARD GELATIN CAPSULE
WARNER-LAMBERT's FIRST PROJECT IN CHINA IS HARD GELATIN CAPSULE manufacturing facility to be established under a joint venture with that country's Natl. Corp. of Pharmaceutical Economic and Technical Internatl. Cooperation (CPIC). The $14 mil. joint venture, announced by Warner-Lambert on July 12, calls for the People's Republic to construct a manufacturing facility for production of empty hard gelatin capsules used in pharmaceutical manufacturing. W-L will supply the machinery and technology to produce the capsules. The W-L agreement is the second drug venture the Chinese have entered into in the past several months. Janssen recently entered a joint venture with three Chinese partners, including CPIC, for the manufacture of 34 Janssen products in the People's Republic of China ("The Pink Sheet" April 29, T&G-10). The W-L/CPIC joint venture, to be called Sino-American Capsugel (Suzhou) Limited, will be located in the city of Suzhou, approximately 45 miles northwest of Shanghai.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth